Loading...
Loading...
In a report published on Friday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating and a price target of $35 on
AmarinAMRN following reports of a positive Statin-Vascepa combo.
In the report, Aegis Capital stated, "This morning, Amarin reported positive data from a Phase 1 clinical trial assessing the pharmacokinetic profile of a fixed-dose combination of the firm's flagship drug product, Vascepa (icosapent ethyl) and a statin (in this case, Crestor or rosuvastatin). This data represents a key cornerstone of Amarin's long- term strategy to eke out a solid market position in the cardiovascular space."
Amarin closed on Thursday at $6.30.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in